Tysabri Returns, But Biogen Idec’s Oral MS Drug Buy May Mean More
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Of the two recent events with major implications for Biogen Idec’s multiple sclerosis franchise, the less prominent – the acquisition of Fumapharm, its partner on the experimental oral MS therapeutic BG-12 – could, in the long run, be more significant than the re-approval of Tysabri.